These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. Management of acute cardiac failure by intracoronary administration of levosimendan. Caimmi PP, Kapetanakis EI, Beggino C, Molinari C, Giustini G, Crosio E, Reposo G, Micalizzi E, Vacca G, Grossini E. J Cardiovasc Pharmacol; 2011 Sep; 58(3):246-53. PubMed ID: 21654504 [Abstract] [Full Text] [Related]
45. [Short and intermediate term clinical outcome in patients with cardiogenic shock treated with aortic counterpulsation]. Fornaro G, Prando MD, Parodi F, Cordero G, Sansa M, Bongo AS, Campi A, Aralda D, Dellavesa P, Aina F, Lazzero M, Cernigliaro C. G Ital Cardiol; 1996 Dec; 26(12):1385-99. PubMed ID: 9162668 [Abstract] [Full Text] [Related]
55. Early 'in-lab' use of levosimendan in patients with cardiogenic shock unsuitable for intra-aortic balloon pump counterpulsation. Summaria F, Mustilli M, Sette A, Lanzillo C, Romagnoli E. Ther Adv Cardiovasc Dis; 2014 Feb; 8(1):28-31. PubMed ID: 24492986 [Abstract] [Full Text] [Related]
56. Mechanical versus pharmacologic support for cardiogenic shock. Dhar G, Jolly N. Catheter Cardiovasc Interv; 2010 Mar 01; 75(4):626-9. PubMed ID: 20049971 [Abstract] [Full Text] [Related]
59. Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Morelli A, De Castro S, Teboul JL, Singer M, Rocco M, Conti G, De Luca L, Di Angelantonio E, Orecchioni A, Pandian NG, Pietropaoli P. Intensive Care Med; 2005 May 01; 31(5):638-44. PubMed ID: 15812624 [Abstract] [Full Text] [Related]
60. [Treatment of cardiogenic shock with the Ca2+ sensitizer levosimendan]. Zobel C, Reuter H, Schwinger RH. Med Klin (Munich); 2004 Dec 15; 99(12):742-6. PubMed ID: 15599685 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]